Idera Pharmaceuticals, Inc. (IDRA)

Oncology Corporate Profile

Stock Performance

1.7700
-0.0200

HQ Location

167 Sidney Street
Cambridge, MA 2139

Company Description

Idera Pharmaceuticals is a clinical stage biotechnology company developing a novel approach to the treatment of autoimmune diseases and certain genetically defined forms of B-cell lymphoma. Our most advanced clinical programs are based on nucleic acid therapeutics designed to inhibit overactivation of Toll-like receptors. Idera is conducting clinical development of TLR antagonists in autoimmune and inflammatory diseases, and preclinical development of their use in certain genetically defined forms of B-cell lymphoma.

Website: http://www.iderapharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
IMO-8400antisense oligonucleotideDiffuse large B-cell Lymphoma (DLBCL)I
IMO-2125 (+ ipilimumab)TLR9 agonistMelanomaI
IMO-8400antisense oligonucleotideWaldenstrom macroglobulinemia (WM)I

Pipeline image

Source


http://www.iderapharma.com/

Recent News Headlines

Idera Pharmaceuticals and XOMA Find Paths to Financial Growth

3/23/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Two stocks that investors gained confidence in on Wednesday are both getting attention from stockholders on recent news announcements. Both the companies may ...

Idera posts 4Q profit

3/15/2017 11:02 pm

Idera posts 4Q profit

3/15/2017 11:02 pm

Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update

3/15/2017 08:03 pm

[GlobeNewswire] - -IM O-2125 Confirmed Responses in PD-1 Refractory Melanoma Appear Durable-. -First Third Generation Antisense Target Selected; Poised to Enter Clinical Development in 2018-. CAMBRIDGE, Mass. and EXTON, ...

Idera to Present at the 37th Annual Cowen and Company Health Care Conference

3/2/2017 12:03 pm

[GlobeNewswire] - CAMBRIDGE, Mass. and EXTON, Pa., March 02, 2017-- Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and ...

Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinic

2/24/2017 04:03 pm

[GlobeNewswire] - ORLANDO, Fla., Feb. 24, 2017-- Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today ...

Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development

2/6/2017 01:00 pm

[GlobeNewswire] - CAMBRIDGE, Mass. and EXTON, Pa., Feb. 06, 2017-- Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and ...

Idera to Present at the 35th Annual J.P. Morgan Healthcare Conference

1/4/2017 05:00 pm

[GlobeNewswire] - CAMBRIDGE, Mass. and EXTON, Pa., Jan. 04, 2017-- Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and ...